AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and price target hike to $38.
Mounjaro Maker Eli Lilly Taps Swedish Firm Camurus To Target Long-Acting Obesity Market In $870-Million Deal Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies targeting metabolic diseases.
IBD 50's Hims & Hers Health Shoots Higher On A Key Takeover In Europe The company hopes the deal will help it snag business in the UK, building a similar model to its U.S. platform.
Looking For Summer Seasonal Gains? Here Are 10 S&P 500 Stocks That Historically Rallied In June Seasonal trends highlight 10 S&P 500 stocks with strong June performance. Tesla leads the list, joined by consistent gainers like Eli Lilly.
Eli Lilly Rises 1.5% After Key Trading Signal A significant trading signal occurred for Eli Lilly stock, as it demonstrated a power inflow at $734.98, after which LLY rose up to 1.5%.
Top S&P500 movers in Friday's session Stay updated with the movements of the S&P500 index one hour before the close of the markets on Friday. Discover which stocks are leading as top gainers and losers in today's session.
Summit Therapeutics, A Top 1% Biotech, Plummets On A High-Profile Failure There's a long history of anti-PD-1 and anti-VEGF drugs working to slow progression, but not improve overall survival.
Regeneron Pharmaceuticals Crashes 12% On A Surprise Sanofi-Tied Failure Regeneron stock crashed Friday after the company's Sanofi-partnered COPD treatment unexpectedly failed in a Phase 3 study.
Novo Nordisk Is Shedding Muscle In The Weight-Loss Brawl With Eli Lilly Eli Lilly is rapidly encroaching on Novo Nordisk's yearslong lead in GLP-1 drugs. Can Novo hold its tentpole position?
Eli Lilly : A Breakout Biotech Powerhouse With Room to Run Eli Lilly's growth is fueled by leading drug sales and a promising pipeline, suggesting a sustained upward trajectory for the pharmaceutical innovator.
Novo Nordisk's 52% Plunge: Is the Company Fumbling Its Leadership in the $150 Billion Weight Loss Market? Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels.
Eli Lilly's May Meltdown Is In History Books — Could June Seasonality Bring A Rebound? Eli Lilly stock down 19% in May, on track for worst month since 2009. But June historically brings better fortune, with 67% chance of closing higher.
